Epidemiology of precancer lesions and genital warts associated with Human papilloma virus infection in Spain;Epidemiología de las lesiones precancerosas y verrugas genitales asociadas a infección por virus del papiloma humano en España

Progresos de Obstetricia y Ginecologia

Volumn 53, Issue 3, 2010, Pages 81-87

  Castellsagué, Xavier ^a   Martín, María San ^b   González, Antonio ^b   Casado, Miguel Ángel ^c  

^a CATALAN INSTITUTE OF ONCOLOGY   (Spain)

^b AUTONOMOUS UNIVERSITY OF MADRID   (Spain)

^c Pharmacoeconomics and Outcomes Research Iberia (PORIB)   (Spain)

Author keywords

Cervical intraepithelial neoplasia; Epidemiology; Genital warts; Human papilloma virus; Spain

Indexed keywords

AGE DISTRIBUTION; ARTICLE; CONDYLOMA ACUMINATUM; CYTODIAGNOSIS; GYNECOLOGY; HUMAN; MORBIDITY; RETROSPECTIVE STUDY; SEX DIFFERENCE; SPAIN; UROLOGY; UTERINE CERVIX CARCINOMA IN SITU; VIRUS INFECTION; WART VIRUS;

EID: 77649234073     PISSN: 03045013     EISSN: 15781453     Source Type: Journal    
DOI: 10.1016/j.pog.2009.07.001     Document Type: Article

References (30)

1. Walboomers J.M., Jacobs M.V., Manos M.M., Bosch F.X., Kummer A., Shah K.V., et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 189 (1999) 12-19
2. Clifford G.M., Smith J.S., Aguado T., and Franceschi S. Comparison of HPV type distribution in high-grade cervical lesions and cervical cancer: a meta-analysis. Br J Cancer. 89 (2003) 101-105
3. Schiffman M., Herrero R., Desalle R., Hildesheim A., Wacholder S., Rodriguez A.C., et al. The carcinogenicity of human papillomavirus types reflects viral evolution. Virology. 337 (2005) 76-84
4. Clifford G.M., Rana R.K., Franceschi S., Smith J.S., Gough G., and Pimenta J.M. Human papillomavirus genotype distribution in low-grade cervical lesions: comparison by geographic region and with cervical cancer. Cancer Epidemiol Biomarkers Prev. 14 (2005) 1157-1164
5. Muñoz N., Bosch F.X., De Sanjose S., Herrero R., Castellsagué X., Shah K.V., et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med. 348 (2003) 518-527
6. Clifford G.M., Smith J.S., Plummer M., Munoz N., and Franceschi S. Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis. Br J Cancer. 88 (2003) 63-73
7. Gissmann L., Wolnik L., Ikenberg H., Koldovsky U., Schnürch H.G., and Zur Hausen H. Human papillomavirus types 6 and 11 DNA sequences in genital and laryngeal papillomas and in some cervical cancers. Proc Natl Acad Sci USA. 80 (1983) 560-563
8. Ferlay J., Bray F., Pisan P., and Parkin D. GLOBOCAN: 2002 Cancer incidence, mortality and prevalence worldwide (2004), IARC, Lyon
9. Wilson F.X. Emerging therapies for human papillomavirus infection. Expert Opin Emerg Drugs. 6 (2001) 199-207
10. Langley P.C., Tyring S.K., and Smith M.H. The cost effectiveness of patient-applied versus provider-administered intervention strategies for the treatment of external genital warts. Am J Manag Care. 5 (1999) 69-77
11. The UK Collaborative Group for HIV and STI Surveillance. A Complex Picture. HIV and other sexually transmitted infections in the United Kingdom: 2006. London: Health Protection Agency, Centre for Infections; 2006.
12. Documento de consenso de las sociedades científicas. Vacunas profilácticas frente a VPH. Enero 2007. Disponible en: http://www.vacunasaep.org/pdf/2007/consenso_sociedades_vacuna%20_vph.pdf
13. Bray F., Loos A.H., McCarron P., Weiderpass E., Arbyn M., Moller H., et al. Trends in cervical squamous cell carcinoma incidence in 13 European countries: changing risk and the effects of screening. Cancer Epidemiol Biomarkers Prev. 14 (2005) 677-686
14. Vizcaíno A.P., Moreno V., Bosch F.X., Munoz N., Barros-Dios X.M., Borras J., et al. Inyernational trends in incidence of cervical cancer: Squamous-cell carcinoma. Int J Cancer. 86 (2000) 429-435
15. Suris J.C., and Dexeus S. Survival in cervical cancer. Eur J Gynaecol Oncol. 19 (1998) 11-13
16. Llorca J., Rodríguez-Cundin P., Dierssen-Soto T., and Prieto-Salceda D. Cervical cancer mortality is increasing in Spanish women younger than 50. Cancer Lett. 240 (2006) 36-40
17. Puig-Tintoré L.M., Castellsagué X., Torné A., De Sanjosé S., Cortés J., Roura E., et al. Coverage and factors associated with cervical cancer screening: results from the AFRODITA study: a population-based survey in Spain. J Low Genit Tract Dis. 12 (2008) 82-89
18. Cantor S.B., Atkinson E.N., Cardenas-Turanzas M., Benedit J.L., Follen M., and MacAulay C. Natural history of cervical intraepithelial neoplasia: a meta-analysis. Acta Cytol. 49 (2005) 405-415
19. Puig-Tintoré L.M., Cortés J., Castellsagué X., Torné A., Ordi J., De Sanjosé S., et al. Prevención del cáncer de cuello uterino, ante la vacunación frente al virus de papiloma humano. Prog Obstet Ginecol. 49 Suppl 2 (2006) 5-62
20. De Sanjosé S., Cortés X., Méndez C., Puig-Tintoré L., Tomé A., Roura E., et al. Age at sexual initiation and number of sexual partners in the female Spanish population. Results from the AFRODITA survey. Eur J Obstet Gynecol Reprod Biol. 140 (2008) 234-240
21. Health Protection Agency Centre for Infections. Diagnoses and rates of selected STIs seen at GUM clinics: 2001-2005. National & Regional Level Summary tables. 22-11-2006.21-5-2007. Ref Type: Internet Communication.
22. Hillemanns P., Breugelmans J.G., Gieseking F., Bénard S., Lamure E., Littlewood K.J., et al. Estimation of the incidente of genital warts and the costo f illness in Germany: a cross-sectional study. BMC Infect Dis. 8 (2008) 76
23. Monsonego J., Breugelmans J.G., Bouée S., Lafuma A., Bénard S., and Rémy V. Anogenital warts incidence, medical management and costs in women consulting gynaecologists in France. Gynecol Obstet Fertil. 35 (2007) 107-113
24. Bergeron C., Breugelmans J.G., Bouee S., Lorans C., Benard S., and Remy V. Cervical cancer screening and associated treatment costs in France. Gynecol Obstet Fertil. 34 (2006) 103642
25. Bergeron C, Cartier I, Guldner L, Lassalle M, Savignoni A, Asselain B. Precancerous lesions and cervical cancer diagnosed by cervical Pap semear, Ile-de-France, Crisap survey [Lèsions précancéreuses et CCs du col de l'utérus diagnostiqués par le frottis cervical], 2002. BEH. 2005; 2:5-6. Disponible en: http://www.invs.sante.fr/beh/2005/02/beh_02_2005.pdf
26. Giorgi-Rossi P, Largeron N, Cohet C, Palazzo F, Mennini FS, Furnari G, Federici A, Valle S. Impact and cost of cervical cancer prevention in Italy. Abstract. 4th Annual Meeting of Health Technology Assessment Internacional (HTAi), Barcelona, Spain, 2007.
27. Brown R.E., Breugelmans J.G., Theodoratou D., and Bénard S. Costs of detection and treatment of cervical cancer, cervical dysplasia and genital warts in the UK. Curr Med Res Opin. 22 (2006) 663-670
28. Petry K.U., Breugelmans J.G., Bénard S., Lamure E., Littlewood K.J., and Hillemanns P. Cost of screening and treatment of cervical dyskaryosis in Germany. Eur J Gynaecol Oncol. 29 (2008) 345-349
29. Petry K.U., Menton S., Menton M., Van Loenen-Frosch F., De Carvalho Gomes H., Holz B., et al. Inclusion of HPV testing in routine cervical cancer screening for women above 29 years in Germany: results for 8466 patients. Br J Cancer. 88 (2003) 15707
30. Volante R., and Ronco G. National survey of the quality of 2nd level in screening for cervical câncer. Epidemiol Prev. 30 Suppl 3 (2006) 51-57